EP Patent

EP2503005A3 — Cortexolone-17alpha-propionate in cristalline hydrate form IV

Assigned to Cassiopea SpA · Expires 2012-10-03 · 14y expired

What this patent protects

The present invention refers to a new enzymatic process for obtaining cortexolone-17α-propionate starting from the corresponding 17α,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to a new crystalline form of cortexo…

USPTO Abstract

The present invention refers to a new enzymatic process for obtaining cortexolone-17α-propionate starting from the corresponding 17α,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to a new crystalline form of cortexolone 17α-propionate.

Drugs covered by this patent

Patent Metadata

Patent number
EP2503005A3
Jurisdiction
EP
Classification
—
Expires
2012-10-03
Drug substance claim
No
Drug product claim
No
Assignee
Cassiopea SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.